ReNetX Bio   Report issue

For profit Phase 2
Founded: New Haven CT United States (2010)

Organization Overview

First Clinical Trial
2019
NCT03989440
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

ReNetX Bio | ReNetX Bio, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

axer-204 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Spinal Cord Injuries (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1